Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

Othman Al-SawafCan ZhangTong LuMichael Z LiaoAnesh PanchalSandra RobrechtTravers ChingManeesh TandonAnna-Maria FinkEugen TauschChristof SchneiderMatthias RitgenSebastian BöttcherKarl-Anton KreuzerBrenda ChylaDale MilesClemens-Martin WendtnerBarbara EichhorstStephan StilgenbauerYanwen JiangMichael HallekKirsten Fischer

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

Appearance of MRD after Ven-Obi is significantly slower than that after Clb-Obi with more effective MRD reduction. These findings translate into a superior long-term efficacy with the majority of Ven-Obi-treated patients remaining in remission.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
chronic lymphocytic leukemia
double blind
peritoneal dialysis
systemic lupus erythematosus
combination therapy
disease activity
phase iii
patient reported outcomes
patient reported